We are analyzing https://link.springer.com/article/10.1007/s11912-020-00969-w.

Title:
Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy | Current Oncology Reports
Description:
Purpose of Review Immunotherapy has revolutionized the treatment of non-surgical stage III and stage IV non-small cell lung cancer (NSCLC). Here, we review emerging data on the safety, feasibility, and efficacy of neoadjuvant immunotherapy in the setting of earlier stage surgically resectable lung cancer. Recent Findings Several small studies support the safety and feasibility of neoadjuvant immunotherapy, noting similar perioperative rates of morbidity and mortality compared with historical controls. Data from several phase II trials have shown high rates of major pathologic response (MPR), though it is unclear if this will correlate with a survival benefit. Phase III trials of neoadjuvant immunotherapy alone or in combination with chemotherapy are ongoing. Summary Neoadjuvant immunotherapy offers a promising treatment modality in earlier stage NSCLC patients. Results of ongoing phase II and phase III trials will be essential in determining how to best integrate this treatment modality in the future.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, article, lung, pubmed, google, scholar, neoadjuvant, cas, nonsmall, cell, chemotherapy, oncol, clin, response, nonsmallcell, immunotherapy, resectable, adjuvant, stage, nsclc, phase, patients, central, thorac, med, treatment, engl, httpsdoiorgnejmoa, surg, data, therapy, earlystage, resected, study, nivolumab, surgery, iii, pathologic, versus, suppl, content, safety, major, survival, surgical, ann, tnm, cardiovasc, criteria, trial,

Topics {✒️}

month download article/chapter org/professionals/physician_gls/pdf/nscl small-cell lung carcinoma small-cell lung cancer small-cell lung cancer immune-related response criteria small-cell lung cancers early-stage lung cancer major pathologic response gov/statfacts/html/lungb post-operative adjuvant chemotherapy lung cancer access full article pdf cisplatin-based adjuvant chemotherapy lace collaborative group revised recist guideline major pathological response surgery versus surgery received research funding national cancer institute pd-l1-positive privacy choices/manage cookies egfr-mutant nsclc primary lung cancer shown high rates complete surgical resection animal subjects performed related subjects hellmann md breast cancer survival iiia completely resected clin lung cancer additional information publisher lung cancer incidence response evaluation criteria small studies support immune therapy activity stage ii-iiia surgical stage iii de miranda nf resectable lung cancer cancer stat facts radiographic response prior pathological complete response patient selection criteria support accelerated approval thoracic cardiovascular surgery meta-analysis underwent surgical assessment osimertinib versus placebo

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy
         description:Immunotherapy has revolutionized the treatment of non-surgical stage III and stage IV non-small cell lung cancer (NSCLC). Here, we review emerging data on the safety, feasibility, and efficacy of neoadjuvant immunotherapy in the setting of earlier stage surgically resectable lung cancer. Several small studies support the safety and feasibility of neoadjuvant immunotherapy, noting similar perioperative rates of morbidity and mortality compared with historical controls. Data from several phase II trials have shown high rates of major pathologic response (MPR), though it is unclear if this will correlate with a survival benefit. Phase III trials of neoadjuvant immunotherapy alone or in combination with chemotherapy are ongoing. Neoadjuvant immunotherapy offers a promising treatment modality in earlier stage NSCLC patients. Results of ongoing phase II and phase III trials will be essential in determining how to best integrate this treatment modality in the future.
         datePublished:2020-08-15T00:00:00Z
         dateModified:2020-08-15T00:00:00Z
         pageStart:1
         pageEnd:9
         sameAs:https://doi.org/10.1007/s11912-020-00969-w
         keywords:
            Non-small cell lung cancer
            Neoadjuvant
            Immunotherapy
            Lung resection
            Surgery
            Major pathologic response
            Oncology
         image:
         isPartOf:
            name:Current Oncology Reports
            issn:
               1534-6269
               1523-3790
            volumeNumber:22
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ryan D. Gentzler
               url:http://orcid.org/0000-0002-8983-6677
               affiliation:
                     name:University of Virginia
                     address:
                        name:Division of Hematology/Oncology, University of Virginia, Charlottesville, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:David O. Riley
               affiliation:
                     name:University of Virginia
                     address:
                        name:Division of Hematology/Oncology, University of Virginia, Charlottesville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Linda W. Martin
               affiliation:
                     name:University of Virginia
                     address:
                        name:Division of Thoracic Cardiovascular Surgery, University of Virginia, Charlottesville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy
      description:Immunotherapy has revolutionized the treatment of non-surgical stage III and stage IV non-small cell lung cancer (NSCLC). Here, we review emerging data on the safety, feasibility, and efficacy of neoadjuvant immunotherapy in the setting of earlier stage surgically resectable lung cancer. Several small studies support the safety and feasibility of neoadjuvant immunotherapy, noting similar perioperative rates of morbidity and mortality compared with historical controls. Data from several phase II trials have shown high rates of major pathologic response (MPR), though it is unclear if this will correlate with a survival benefit. Phase III trials of neoadjuvant immunotherapy alone or in combination with chemotherapy are ongoing. Neoadjuvant immunotherapy offers a promising treatment modality in earlier stage NSCLC patients. Results of ongoing phase II and phase III trials will be essential in determining how to best integrate this treatment modality in the future.
      datePublished:2020-08-15T00:00:00Z
      dateModified:2020-08-15T00:00:00Z
      pageStart:1
      pageEnd:9
      sameAs:https://doi.org/10.1007/s11912-020-00969-w
      keywords:
         Non-small cell lung cancer
         Neoadjuvant
         Immunotherapy
         Lung resection
         Surgery
         Major pathologic response
         Oncology
      image:
      isPartOf:
         name:Current Oncology Reports
         issn:
            1534-6269
            1523-3790
         volumeNumber:22
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ryan D. Gentzler
            url:http://orcid.org/0000-0002-8983-6677
            affiliation:
                  name:University of Virginia
                  address:
                     name:Division of Hematology/Oncology, University of Virginia, Charlottesville, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:David O. Riley
            affiliation:
                  name:University of Virginia
                  address:
                     name:Division of Hematology/Oncology, University of Virginia, Charlottesville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Linda W. Martin
            affiliation:
                  name:University of Virginia
                  address:
                     name:Division of Thoracic Cardiovascular Surgery, University of Virginia, Charlottesville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Oncology Reports
      issn:
         1534-6269
         1523-3790
      volumeNumber:22
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Virginia
      address:
         name:Division of Hematology/Oncology, University of Virginia, Charlottesville, USA
         type:PostalAddress
      name:University of Virginia
      address:
         name:Division of Hematology/Oncology, University of Virginia, Charlottesville, USA
         type:PostalAddress
      name:University of Virginia
      address:
         name:Division of Thoracic Cardiovascular Surgery, University of Virginia, Charlottesville, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ryan D. Gentzler
      url:http://orcid.org/0000-0002-8983-6677
      affiliation:
            name:University of Virginia
            address:
               name:Division of Hematology/Oncology, University of Virginia, Charlottesville, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:David O. Riley
      affiliation:
            name:University of Virginia
            address:
               name:Division of Hematology/Oncology, University of Virginia, Charlottesville, USA
               type:PostalAddress
            type:Organization
      name:Linda W. Martin
      affiliation:
            name:University of Virginia
            address:
               name:Division of Thoracic Cardiovascular Surgery, University of Virginia, Charlottesville, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Hematology/Oncology, University of Virginia, Charlottesville, USA
      name:Division of Hematology/Oncology, University of Virginia, Charlottesville, USA
      name:Division of Thoracic Cardiovascular Surgery, University of Virginia, Charlottesville, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(256)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js
Video.js

CDN Services {📦}

Crossref

5.17s.

LINK . SPRINGER . COM {}